RAPT Therapeutics stock rises after Leerink upgrades on food allergy opportunity
PositiveFinancial Markets

RAPT Therapeutics saw a significant boost in its stock price following an upgrade from Leerink, which highlighted the company's promising potential in addressing food allergies. This upgrade is important as it reflects growing confidence in RAPT's innovative approaches and could attract more investors, ultimately benefiting the company's growth and the development of new treatments for food allergies.
— Curated by the World Pulse Now AI Editorial System